Banyan BioInnovations Pursues Emerging Biotech Assets in China

Geoff Meyerson, CEO of Banyan BioInnovations, is actively pursuing biotech investment opportunities in China as part of the firm's strategy to launch new companies around promising drug assets. The fund has committed $100 million and plans two to three deals annually.

By Meagan Parrish Fri, July 17, 2026 at 12:43 PM GMT+3 5 min read · Yahoo Finance · July 17, 2026, 09:43 UTC

Banyan BioInnovations Pursues Emerging Biotech Assets in China

Topics: biotechnology China market expansion investment funds

Read the full article at Yahoo Finance

More Business news

Kennedy Funding Closes $5.625 Million Land Loan for Dominican Republic Tourism Project PR Newswire · November 12, 2026, 16:14 UTC
Norwest Raises Record $4 Billion Fund Focused on Artificial Intelligence Expansion TechCrunch · November 12, 2026, 15:18 UTC
U.S. Existing Home Sales Fall to 16-Year Low in October MarketWatch · November 12, 2026, 15:01 UTC
Bronstein Properties Acquires The Gardens Shopping Center in New Jersey for $41 Million PR Newswire · November 12, 2026, 13:48 UTC
Acre NY Realty Announces Groundbreaking for New Residential Development in Long Island City PR Newswire · November 12, 2026, 13:44 UTC
Clever Real Estate Reaches $250 Million in Cumulative Savings Milestone for Home Sellers PR Newswire · November 12, 2026, 13:41 UTC
Anthropic Announces Initial Public Offering Scheduled for November 19 The Verge · November 12, 2026, 13:37 UTC
Caregiving Costs Rise 59% Since 2021, Driving Significant Financial Stress for Employees PR Newswire · November 12, 2026, 13:04 UTC
Redfin Report: U.S. Home Prices and Mortgage Payments Decline for Four Consecutive Weeks PR Newswire · November 12, 2026, 13:00 UTC
Broe Real Estate Group Acquires Luxury Maple Terrace Residences in Dallas PR Newswire · November 12, 2026, 13:00 UTC